Anthem Biosciences (ANTHEM) Q4 24/25 earnings summary

Executive summary

• FY25 revenue from operations rose 30% YoY to ₹18,446 million; EBITDA was ₹7,566 million and PAT ₹4,513 million.

• CRDMO and Specialty Ingredients both contributed to growth, with CRDMO the primary revenue driver and over 71% of revenue from development and commercial manufacturing.

• The integrated platform had executed 8,000+ projects for 675+ customers and supported around 200 active programmes across drug-development stages.

Financial highlights

• Consolidated revenue from operations was ₹18,445.5 million versus ₹14,193.7 million in FY24; total income was ₹19,302.8 million versus ₹14,830.7 million.

• Consolidated PAT increased 22.9% YoY to ₹4,512.6 million; PBT was ₹6,568.7 million and tax expense ₹2,056.1 million.

• Standalone revenue from operations grew 29.8% to ₹18,406.5 million; standalone PAT rose 35% to ₹5,061.9 million.

• EBITDA was ₹7,566 million, with a 39.19% margin; PAT margin was 23.38%.

• Consolidated operating cash flow was ₹4,183.4 million; capital expenditure and other fixed-asset purchases used ₹3,145.3 million.

Outlook and guidance

• Fermentation capacity is expected to rise from 140 kL to 182 kL by mid-to-late FY26.

• Unit II’s 130 kL custom-synthesis expansion is progressing in phases: 54 kL commissioned in April 2025; the remaining 76 kL expected by mid-to-late FY26.

• Unit III development is phased; commercial peptide and high-potency manufacturing was targeted for commissioning within the next quarter, with further capacity build-out planned.